VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vir Biotechnology Inc (VIR) is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts such as analyst upgrades and promising clinical data, the recent stock offering, insider and hedge fund selling, and financial losses create significant headwinds. The technical indicators suggest a neutral to slightly bullish trend, but the lack of strong proprietary trading signals and mixed sentiment from options and trading data make it prudent to hold off on investing right now.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 67.379, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 8.751, R1: 10.218, S1: 7.284. However, the pre-market price is down 2.15%, reflecting short-term weakness.
Multiple analyst upgrades with increased price targets (ranging from $17 to $30).
Promising clinical data for VIR-5500, positioning it as a potential leader in prostate cancer treatment.
New partnership with Astellas, including $335M in upfront payments and profit-sharing agreements.
Recent stock offering at $8.50 per share, leading to a 13.30% stock drop.
Significant insider and hedge fund selling activity.
Financial losses in Q4 2025, with net income down 58.96% YoY and EPS down 59.21% YoY.
In Q4 2025, revenue increased significantly by 417.78% YoY to $64.07M, but net income dropped by 58.96% YoY to -$42.92M. EPS also declined by 59.21% YoY to -0.31. Gross margin improved slightly to 99.96%, up 5.81% YoY.
Analysts are bullish on VIR, with multiple upgrades and increased price targets (e.g., Barclays raised to $30, Raymond James upgraded to Strong Buy with a $19 target). The consensus highlights the promising clinical data and new partnership as key growth drivers.
